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SIGLEC1 (CD169): a marker 
of active neuroinflammation 
in the brain but not in the blood 
of multiple sclerosis patients
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We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis 
optica spectrum disorder (NMOSD) and to evaluate the presence of  SIGLEC1+ myeloid cells in 
demyelinating diseases. We performed flow cytometry‑based measurements of SIGLEC1 expression 
on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we 
histologically evaluated the presence of  SIGLEC1+ myeloid cells in acute and chronic MS brain lesions 
as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS 
patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received 
exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS 
patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 
expression on monocytes was—apart from those patients receiving interferon treatment—not 
significantly increased in patients with MS and NMOSD, nor were levels associated with more severe 
disease.  SIGLEC1+ myeloid cells were abundantly present in active MS lesions as well as in a range of 
acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. 
The presence of  SIGLEC1+ myeloid cells in brain lesions could be used to investigate the activity in an 
inflammatory CNS lesion.
Multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) are both chronic, demyelinating 
inflammatory diseases of the central nervous system that are a significant cause of disability in the young. While 
certain aspects of the pathophysiology of both diseases have been uncovered, many aspects towards a complete 
understanding remain to be  elucidated1.
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SIGLEC1 (Sialic acid-binding immunoglobulin-type lectins-1, CD169) is a sialic acid binding cell-surface 
protein, exclusively expressed on monocytes and  macrophages2. Its expression is upregulated upon contact with 
type I interferons and to a lesser degree, other activatory stimuli such as  LPS3,4. As such, SIGLEC1 expression 
has been used as a surrogate marker for type I interferon activity in autoimmune diseases like Systemic lupus 
 erythematosus5 or primary Sjögren  syndrome6 as well as  interferonopathies7 and viral  infections8,9.
In the healthy brain, SIGLEC1 is only expressed by some perivascular and choroid plexus macrophages, but 
not by  microglia10. In mice, mechanical insult to the brain led to an accumulation of  SIGLEC1+ myeloid cells in 
the damaged  area10. The cause of this accumulation, however, is unclear—either the contact of serum components 
or inflammatory signals with resident myeloid cells induces SIGLEC1 expression or blood-derived  SIGLEC1+ 
myeloid cells infiltrate the CNS.
The role of type I interferons and SIGLEC1 in the pathophysiology of MS and NMOSD is not yet clear. In 
relapsing–remitting MS (RRMS), type I interferons are used as an immunomodulatory treatment that reduces 
the rate of  relapses11. It does, however, not protect against clinical progression in the progressive forms of MS 
(primary progressive MS (PPMS) and secondary progressive MS (SPMS))11. In a recent report, SIGLEC1 positive 
myeloid cells were found within MS lesions and specific ablation of SIGLEC1 expressing cells in the experimental 
autoimmune encephalitis (EAE) model of MS led to an amelioration of  disease12. Additionally, plasmacytoid 
dendritic cells, the main type I interferon-producing cells, were found in increased frequencies in the cerebro-
spinal fluid of MS patients during a  flare13. Two studies found SIGLEC1 expression to be increased on blood 
monocytes of MS patients, especially those with a progressive type of  MS12,14. Taken together, there is conflicting 
evidence on the role of type I interferons and the interferon-induced expression of SIGLEC1 in MS as being 
protective or pathogenic. This is likely due to the heterogeneity of patients and disease stages and potentially 
also the confounding effect of interferon therapy.
In NMOSD, there is some evidence that type I interferons play a role in its pathogenesis: many patients with 
NMOSD have an overlap with additional, type I interferon-dependent diseases, such as  SLE15 and a recent report 
describes a series of patients with increased levels of endogenous or exogenous interferon α who went on to 
develop a seropositive  NMOSD16. Interferon treatment does not prevent NMOSD  relapses17 and anecdotally even 
increases the disease  activity18. Transcriptomic profiling of blood from NMOSD patients identified a “interferon 
high” signature in 16 of 38 (42.1%) of NMOSD  patients19. This signature included the transcript for SIGLEC1 
and was associated with higher disease severity. Additionally, we recently described the presence of low-density 
granulocytes in MS and NMOSD  patients20, a subset of granulocytes that produce high levels of type I interferons 
in  SLE21. Thus, we hypothesized that type I interferons could also play a role in the pathogenesis of NMOSD.
In this work we investigated expression of SIGLEC1 on monocytes of patients with MS and NMOSD and 
correlated the expression with clinical parameters. In addition, we analysed human brain tissue sections of active, 
inflammatory and chronic MS lesions as well as other neurological and systemic diseases.
Results
SIGLEC1 expression is increased in a subset of patients with multiple sclerosis. We investi-
gated the SIGLEC1 expression on  CD14+ monocytes in the peripheral blood of MS and NMOSD patients as 
well as in healthy controls. In most of the samples, monocyte SIGLEC1 expression was barely above the nega-
tive (fluorescence minus one) control (Fig.  1a,b). We defined a physiologic range of SIGLEC1 expression as 
two standard deviations from the mean SIGLEC1 expression in healthy controls (normal MFI range 0–564). 
Accordingly, 16/86 (18.6%) MS patients, 4/41 (9.8%) NMOSD patients and 1/31 (3.2%) healthy controls had 
increased SIGLEC1 levels. Almost all individuals with available longitudinal samples remained in their respec-
tive SIGLEC1 high or low category over a follow-up period of up to 1965 days. (Fig. 1c).
Treatment with type 1 interferon explains almost all increased. Next, we aimed to identify param-
eters that were associated with increased SIGLEC1 in MS patients. One obvious explanation would be exogenous 
type 1 interferon as treatment. 11/16 MS patients (68.6%) with increased SIGLEC1 expression levels received 
interferon beta treatment at the time of measurement (Fig.  1d). While a previous report found increased 
SIGLEC1 levels to be more prevalent in MS patients with a progressive form of MS, we found only 2/20 patients 
primary or secondary progressive MS with increased SIGLEC1 levels that were not explained by interferon treat-
ment (Fig. 1e). SIGLEC1 expression on monocytes did not correlate with the Expanded Disability Status Scale 
(EDSS) (Fig. 1f), nor had it a temporal association with relapses. In the NMOSD patients, one of the four patients 
with increased SIGLEC1 expression had the additional diagnosis of a mixed connective tissue disease (MCTD), 
a disease that is also associated with increased type 1 interferon  activity22.
SIGLEC1 expression on brain‑infiltrating myeloid cells. To investigate the presence and specificity of 
SIGLEC1+ myeloid cells in inflammatory MS lesion, we analysed brain tissue sections from 4 patients with MS 
lesions that had clinical, radiological and histological signs of activity (gadolinium uptake on MRI imaging, pres-
ence of myelin-laden macrophages), 5 patients with secondary-progressive MS (SPMS) who died of acute non-
neurologic causes and with histologically classified chronic lesions and 6 patients who died of cardiovascular or 
multi-organ failure. In all control samples, SIGLEC1 positivity was limited to cells in the leptomeninges as well 
as perivascular macrophages, as previously  reported10. In all four samples from patients with active MS lesions 
as well as in one patient with the Marburg variant of MS who died of the disease 14 days after onset, we found 
a dense infiltrate of CD68+HLA-DR+ myeloid cells that stained predominantly positive for SIGLEC1 (Fig. 2a). 
In contrast, in five samples from patients with secondary-progressive MS (SPMS) with histologically classified 
chronic lesions, we found CD68+HLA-DR+ infiltrates of varying density, but almost no SIGLEC1 expression 
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(Fig. 2a). This indicates that SIGLEC1 expression on myeloid cells could be used to distinguish active inflamma-
tory lesions from chronic lesions.
To corroborate this hypothesis, we studied the SIGLEC1 expression in the brain tissue of 8 patients with 
other inflammatory neurological diseases. SIGLEC1+ myeloid infiltrates were present in patients with glioblas-
toma (n = 2), herpes simplex encephalitis (n = 2) and cerebral infarction (n = 2), as well as toxoplasmosis (n = 1), 
cerebral abscess (n = 2) and post-transplant lymphoproliferative disorders (n = 1, PTLD, Fig. 2b). No increase in 
SIGLEC1+ cells was noted in the brain of a patient who died of amyotrophic lateral sclerosis (ALS).
In summary, SIGLEC1+ is expressed on brain-infiltrating myeloid cells in a broad range of active inflamma-
tory lesions, but not in chronic MS lesions.
Discussion
Here, we report that, after accounting for interferon treatment, patients with multiple sclerosis (MS) and neu-
romyelitis optica spectrum disorder (NMOSD) did not have increased expression of SIGLEC1 on monocytes 
in the peripheral blood.
We identified SIGLEC1+ on CD68+ HLA-DR+ myeloid cells in active inflammatory MS lesions and a range 
of other inflammatory, infectious or malignant brain lesions. SIGLEC1+ expression was low on myeloid cells in 
chronic MS lesions of SPMS patients, indicating that SIGLEC1+ myeloid cells could serve as a marker of inflam-
matory activity. These findings are in line with a previous report that found SIGLEC1+ MHC-II+ myeloid cells 
to be present in mice after retinal transplantation, but not in the healthy retina or retinal  degeneration23. Future 
studies will be needed to investigate, whether the increase in SIGLEC1+ cells in inflammatory brain lesions is 
due to the infiltration of SIGLEC1+ cells from the peripheral blood or an upregulation of SIGLEC1 in tissue-
resident microglia, as well as define the inflammatory signals leading to such an upregulation. We propose that 
SIGLEC1+ can serve as a marker to differentiate active from inactive MS lesions, which will require additional 
validation for use in routine histopathological diagnostics.
Our results on SIGLEC1 expression on blood monocytes are in contrast to two previous reports which iden-
tified increased levels of SIGLEC1 in cohorts of 44 MS  patients12,14. The study by Malhotra et al.14 focussed on 
Figure 1.  (a) Representative histograms of SIGLEC1 fluorescence on  CD14high monocytes, FMO: fluorescence 
minus one control. (b) Cross-sectional analysis of SIGLEC1 expression on  CD14high monocytes of 31 
healthy controls, 86 MS patients and 41 NMOSD patients. If multiple samples of the same individual were 
analysed, the mean of the measurements is displayed. (c) Longitudinal analysis of SIGLEC1 expression of 52 
individuals with up to five measurements. (d) Comparison of SIGLEC1 expression in MS patients, receiving 
no immunomodulatory treatment (n = 24), interferon beta (n = 13) or a non-interferon treatment (n = 49). 
Treatment with interferon with significantly associated with higher levels of SIGLEC1 expression: Kruskal–
Wallis test with Dunn’s correction, **p < 0.01, ****p < 0.0001. (e) Comparison of SIGLEC1 expression in patients 
with RRMS (n = 63), SPMS (n = 15) and PPMS (n = 5). Red symbols indicate interferon treatment. (f) Scatter plot 
of the EDSS disability score against SIGLEC1 expression, no significant correlation was detected.
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Figure 2.  (a) Representative immunohistochemical stainings of CD68, HLA-DR and SIGLEC1 (CD169) in 
brain tissue from a patient with active inflammatory multiple sclerosis lesion, a chronic lesion from a patient 
with secondary-progressive multiple sclerosis (SPMS) and a control patient who died of cardiovascular disease 
(CVD). Both RRMS and SPMS show infiltrates with  CD68+ and HLA-DR+ myeloid cells, but only in the active 
lesion, these express SIGLEC1. Nuclei are stained blue and the respective marker antigens in brown. The scale bar 
indicates 100 µm. These results are representative of 4 RRMS, 5 SPMS and 7 control samples that were examined. 
(b) Immunohistochemical stainings of SIGLEC1 in brain tissue from patients with Herpes simplex viral 
encephalitis (n = 2), cerebral infarction with inflammatory changes (n = 2), cerebral toxoplasmosis (n = 1), cerebral 
abscess (n = 2), glioblastoma (n = 2) and post-transplant lymphoproliferative disease (PTLD, n = 1). Infiltrates of 
 SIGLEC1+ myeloid cells were observed in all samples.
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untreated MS patients and identified modest increases in SIGLEC1 expression in MS patients (approximately 
twofold increase of MFI between MS patients and HC) and especially those with progressive disease. A sec-
ond study by Bogie et al.12 again identified small (approximately twofold) increases in SIGLEC1 expression on 
monocytes in 57 MS patients and found that these increases were independent of progressive disease and also of 
interferon treatment, an observation that is at odds with our own findings and biological plausibility.
This disparity might be due to different reasons: it could be that the authors mostly observed small differ-
ences between individuals that would have all been classified as “SIGLEC1 low expressors” in our study, as the 
approximately twofold-differences they describe are significantly smaller compared to the five–tenfold increases 
in SIGLEC1 MFI in “SIGLEC1 high expressors” in our study. Different studies investigated the SIGLEC1 expres-
sion using different antibody clones which could also explain some of the differences; in this study, we used the 
same clone as previous studies that investigated SIGLEC1 in rheumatologic  diseases5,6.
Additionally, our data are at odds with a previous report that found a type 1 interferon signature in NMOSD 
patients that was conducted with patients from the same patient  cohort19. While 42% of NMOSD cohorts in the 
study by Agasing et al. showed an “high type 1 interferon” signature, we found < 10% of NMOSD patients had 
increased type 1 interferon activity as measured by SIGLEC1 expression; a result that is neither significantly dif-
ferent from healthy controls, nor likely of clinical consequence. As the results of whole blood bulk transcriptomic 
data are often subject to unforeseen external influences and changes in the cellular composition of the blood, 
they should usually be validated by protein level data.
Even though our data are not in agreement with multiple, previously published results, the validity of our 
assay is supported by the internal plausibility control of interferon treated MS patients. However, one significant 
weakness of our own study is the relative clinical quiescence of the patients enrolled; most did not have a relapse 
within the last six months before the measurement and most did not have a change in EDSS in longitudinal sam-
pling. Additionally, most patients were under immunosuppressive treatment. Future studies in MS and NMOSD 
patients during a clinical relapse could thus still discover the presence of SIGLEC1 expressing monocytes in the 
peripheral blood.
In summary, our data indicate that type I interferons or SIGLEC1 expressing cells in the peripheral blood 
do not play a major role in the pathogenesis of most patients with stable NMOSD or MS, however  SIGLEC1+ 
myeloid cells in the brain are present in active inflammatory MS lesions as well as in other inflammatory neu-
rological diseases of the CNS.
Methods
Cohort. We analysed frozen peripheral blood mononuclear cells (PBMCs) from a total of 86 MS patients, 
41 NMOSD patients and 31 healthy controls (HCs) that were included in observational cohort studies for MS 
and NMOSD at the NeuroCure Clinical ResearchCenter, Charité—Universitätsmedizin Berlin. PBMCs from all 
patients with sufficient available material were included in the study with no prior selection according to disease 
activity, treatment, age or sex. All MS patients fulfilled the 2017 revised McDonald  criteria24, while the NMOSD 
patients fulfilled the 2015 Wingerchuck international consensus diagnostic  criteria25. Further patient character-
istics are provided in Table 1.
Longitudinal samples were available for 28/86 MS patients, 12/41 NMOSD patients and 12/31 healthy con-
trols. Follow-up periods were up to 1965 days and included 2 to 5 time points.
PBMC isolation and flow cytometry. Peripheral blood mononuclear cells (PBMCs) were isolated from 
EDTA anticoagulated blood. Blood and phosphate-buffered saline supplemented with 0.5% bovine serum albu-
Table 1.  Epidemiological data. IQR interquartile range, RRMS relapse-remitting multiple sclerosis, SPMS 
secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, AQP4+ aquaporin-4 
antibody positive, MOG+ myelin oligodendrocyte glycoprotein antibody positive, MCTD mixed connective 
tissue disease).
Healthy controls MS patients NMOSD patients
Number of individuals 31 86 41
Age (median, IQR) 31 (27–34) 45 (34–52) 57 (45–64)









Additional immune-mediated diseases (n) Autoimmune thyroiditis (2), asthma bronchiale (1)
Autoimmune thyroiditis (10), asthma 
bronchiale (2), psoriasis (1), idiopathic 
myocarditis (1), celiac disease (1)
Autoimmune thyroiditis (3), myasthenia 
gravis (1), Sjögren syndrome (1), MCTD (1)
Immunosuppressive medication (n) –
None: 24 (27.9%)
Dimethyl fumarate: 15 (17.4%), glatiramer 
acetate: 14 (16.3%), interferon beta: 13 
(15.1%), fingolimod: 7 (8.1%), terifluno-
mide: 5 (5.8%), methylprednisolone: 2 
(2.3%), daclizumab: 2 (2.3%), rituximab: 1 
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min (PBS/BSA) were mixed at a 1:1 ratio and 35 ml were layered onto 15 ml Ficoll-Paque PLUS gradient (GE 
Healthcare). PBMCs were isolated according to the manufacturer’s protocol and stored in liquid nitrogen until 
the analysis.
For analysis batches of 20–35 samples were thawed and washed in RPMI 1640 cell medium (Gibco). In each 
batch, a mix of samples from healthy controls and MS/NMOSD patients were included. Cells were stained 
with antibodies against CD14 (DRFZ, clone TM1), CD169 (SIGLEC1, clone 7–239, BioLegend Cat# 346004, 
RRID:AB_2189029) and a dead cell stain (eBioscience Fixable Viability Dye eFluor 780). For each batch, a fluo-
rescence minus one (FMO) control for SIGLEC1 was measured and FMO measurements remained stable over 
multiple batches. The samples were acquired on a FACSCanto cytometer (BD Biosciences) and all cytometry 
experiments were performed according to published  standards26. Using the FlowJo software (Version 10.4.1 for 
Mac, FlowJo LLC), we identified monocytes and excluded doublets based on scatter parameters. We then gated 
on  CD14high, living cells and analysed the median fluorescence intensity (MFI) for SIGLEC1 (Fig. 1a).
Histology of human brain tissue. We investigated archived cryo- and formalin preserved biopsy and 
autopsy tissue from patients who had been diagnosed in the Department of Neuropathology, Charité—Univer-
sitätsmedizin Berlin with inflammatory demyelination of the central nervous system (CNS) consistent with mul-
tiple sclerosis or other inflammatory, malignant or infectious diseases of the CNS (other neurological disease, 
OND). Tissue that was categorized as active MS lesions stemmed from patients with clinical and MRI evidence 
of active disease with gadolinium contrast agent uptake and/or perifocal edema in T2-weighted sequences. These 
tissue samples were all derived from diagnostic biopsies that were performed to diagnose an unclear tumefac-
tive lesion that was diagnosed as inflammatory demyelinating lesion. After follow-up, these patients were then 
clinically diagnosed with MS. Histologically these lesions showed all active demyelination with myelin laden 
macrophages. In contrast, the patients with lesions categorized as chronic MS lesions were patients diagnosed 
with SPMS that had died of a non-neurologic cause and where only chronically active or inactive lesions with 
lack of myelin-laden macrophages were  analysed27. Patients who died of cardiovascular cases or multi-organ 
failure served as controls. All patients with multiple sclerosis fulfilled clinical diagnosis criteria according to the 
2017 revised McDonald  criteria24 and none of the patients were treated with interferon.
Immunohistology of human brain tissue. All stains were performed on 8  μm cryomicrotome sec-
tions or 4-μm-thick FFPE tissue sections according to standard procedures. Stains included Hematoxylin and 
eosin (H&E), CD68 (EBM11, Dako #M0718, 1:100), HLA-DR (CR3/43; Dako #M0775, 1:200) and SIGLEC1 
(HSn7D2, Novus Biologicals, 1:200). Immunohistochemical stainings were performed on a Benchmark XT 
autostainer (Ventana Medical Systems, Tuscon, AZ, USA) with standard antigen retrieval methods for the FFPE 
sections (CC1 buffer, pH8.0, Ventana Medical Systems, Tuscon, AZ, USA). The presence of SIGLEC1 perivascu-
lar and leptomeningeal staining served as an internal quality control. Microscopy was performed on a BZ-9000 
BioRevo microscope (Keyence, Neu-Isenburg, Germany). Positively stained cells were defined by presence of a 
nucleus and cytoplasmic staining.
Data analysis. Statistical analyses were performed using Python 3.7.6 with the Numpy (v1.19.0)28 and Pan-
das (v1.1.0)29 packages as well as GraphPad Prism (v8.4.3. for Mac). A normal range for SIGLEC1 expression 
in FACS expression was calculated as two standard deviations from the mean SIGLEC1 expression in healthy 
controls. When multiple measurements of the same individual were available, the mean of the measurements 
was calculated and used for comparative analysis. The Chi-squared test or Kruskal–Wallis test with Dunn’s cor-
rection was used to compare between the different groups for binary and continuous variables respectively.
Ethics approval and consent to participate. The analysis of blood was approved by the ethics commit-
tee of the Charité—Universitätsmedizin Berlin (MS: EA1/163/12; NMOSD: EA1/041/14) and informed consent 
was obtained from all participants in the study. The study of brain histology was approved approved by the ethics 
committee of the Charité—Universitätsmedizin (EA1/078/16). This study was performed in accordance with all 
relevant guidelines and regulations, such as the Declaration of Helsinki and the Good Clinical Practice guide-
lines of the International Council for Harmonization.
Data availability
All datasets used and analysed during the current study are available from the corresponding authors on request.
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